ImageneBio, Inc. (NasdaqCM: IMA)
Health Care · Pharmaceuticals · US
$5.55
-4.97% today · -60.3% 1Y
ImageneBio, Inc. (NasdaqCM: IMA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $66.29M and employs 17 people.
Over the last twelve months the share price has lost 60.3%, trading between 3.94 and 15.79.
Tweenvest scores ImageneBio, Inc. across four factors: quality 28/100. Its strongest factor is quality.
IMA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $66.29M
- Revenue (TTM)
- $0.00
- P/E
- —
- EPS
- -5.93
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $15.79
- 52-week low
- $3.94
- Avg volume (3M)
- —
- Shares outstanding
- 11.35M
- Employees
- 17
- Next earnings
- —
About ImageneBio, Inc.
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.
- ISIN
- US45175G2075
- Listed since
- Feb 27, 1998
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.